Case Report

From Confusion to Diplopia and Vertigo: Suspected Central Nervous System Infections Following Obinutuzumab in Systemic Lupus Erythematosus: A Case Report of Two Patients

DOI https://doi.org/10.70302/jpsim.v7i4.2670
Received: 09 Jun 2026 Revised: 22 Aug 2026 Accepted: 28 Oct 2026 Published Online: 20 Nov 2026

Abstract

Obinutuzumab, a type II anti-CD20 monoclonal antibody, causes prolonged B-cell depletion and is increasingly used in systemic lupus erythematosus (SLE) and lupus nephritis. Central nervous system (CNS) infection is a concern and is hard to distinguish from neuropsychiatric lupus. We report two women with SLE and lupus nephritis who developed neurological symptoms about five weeks after obinutuzumab. A 42-year-old woman presented with confusion, headache and fever; imaging suggested frontal and occipital pyogenic abscesses with midline shift. A 29-year-old woman presented with headache, diplopia and vertigo; MRI showed multiple brainstem-predominant lesions, some ring-enhancing. Lumbar puncture was deferred in both because of mass effect or risk of coning, and no microbiological diagnosis was obtained; a brain biopsy in the second patient was non-diagnostic. Both improved with empirical antimicrobial therapy. New neurological symptoms during B-cell-depleting therapy warrant early neuroimaging and consideration of CNS infection. The temporal association does not establish causation.

Keywords:
Lupus Erythematosus Systemic Lupus Nephritis Obinutuzumab

How to Cite This Article

Haroon M, Saeed A, Ahmed NM, Farman S. From Confusion to Diplopia and Vertigo: Suspected Central Nervous System Infections Following Obinutuzumab in Systemic Lupus Erythematosus: A Case Report of Two Patients. J Pak Soc Intern Med. 2026;7(4):352–354. doi:10.70302/jpsim.v7i4.2670

⭳ Download XML (JATS)

Conflict of Interest

None

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

None

Funder information follows the Crossref Funder Registry standard.

Author Contributions

MH: Conception.
AS: Design of the work.
NMA, SF: Data acquisition, analysis, or interpretation.
MH, AS, SF: Draft the work.
NMA: Review critically for important intellectual content.
All authors approve the version to be published.
All authors agree to be accountable for all aspects of the work.

Contributions are recorded against the ICMJE criteria for authorship.

Patient Consent

Informed consent for publication of clinical details was obtained from both patients.

References

  1. Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Martínez G, Zuta Santillán AE, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471-83.
  2. Erbasan F. Brain abscess caused by Micrococcus luteus in a patient with systemic lupus erythematosus: case-based review. Rheumatol Int. 2018;38(12):2323-8.
  3. Li Z, Li D, Lv P, Liu J. Brain abscess due to Nocardia in a patient with systemic lupus erythematosus. J Rheumatol. 2022;49(4):432-3.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. Authors retain copyright. © 2026 The Author(s).